Seelos Therapeutics delisting from Nasdaq and transferring to OTCQB market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 15 2024
0mins
Delisting from Nasdaq: Seelos Therapeutics has been notified by the Nasdaq Hearings Panel that its common stock will be delisted due to non-compliance with minimum stockholder's equity requirements.
Transition to OTCQB: Trading of Seelos Therapeutics' common stock will be suspended on Nasdaq starting October 16, and it is expected to begin trading on the OTCQB market on the same date.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
